Residual anti-Xa activity in plasma of patients presenting for electively planned neuraxial regional anesthesia
Authors' conclusion
Relevant residual anticoagulant activity, as measured by plasma anti-Xa levels within a prophylactic range, is measurable 24 hours after the last administration of therapeutic dose low-molecular-weight heparin.
Study context
- Population
- Patients who received therapeutic dose LMWH before planned neuraxial anesthesia, Freiburg University Hospital, April 2015–April 2020
- Participants
- 74 patients
- Outcome
- Elevated plasma anti-Xa levels in prophylactic range or higher (>0.2 IU/mL)
- Follow-up
- 24 hours after the last application of the therapeutic dose
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Anti-Xa activity >0.2 IU/mL · 24 hours after last therapeutic dose
Patients with elevated anti-Xa activity >0.2 IU/mL
18.0%
Observational data: associations, not effects.
Further findings
Association of time since last LMWH dose with plasma anti-Xa levels
- Weak correlation between time since last dose and plasma anti-Xa levels
Other risk factors
- No other risk factors seen
Original publication
Residual anti-Xa activity in plasma of patients presenting for electively planned neuraxial regional anesthesia. Reg Anesth Pain Med. Published 27 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →